




RealRate

# PHARMACEUTICAL 2023

BeiGene Ltd.  
Rank 174 of 446





RealRate

# PHARMACEUTICAL 2023

BeiGene Ltd.  
Rank 174 of 446



The relative strengths and weaknesses of BeiGene Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BeiGene Ltd. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 30% points. The greatest weakness of BeiGene Ltd. is the variable Intangible Assets, reducing the Economic Capital Ratio by 8.6% points.

The company's Economic Capital Ratio, given in the ranking table, is 131%, being 88% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	5,207,078
Cost of Goods Sold	286,475
Intangible Assets	40,616
Liabilities, Current	1,468,528
Liabilities, Non-Current	527,407
Other Assets	285,650
Other Compr. Net Income	-95,367
Other Expenses	43,529
Other Liabilities	0
Other Net Income	-171,372
Other Revenues	1,415,921
Property and Equipment	845,946
Research and Development	1,640,508
Selling, General and Administrative Expense	1,277,852

Output Variable	Value in 1000 USD
Assets	6,379,290
Liabilities	1,995,935
Expenses	3,248,364
Revenues	1,415,921
Stockholders Equity	4,383,355
Net Income	-2,003,815
Comprehensive Net Income	-2,051,498
Economic Capital Ratio	131%